60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 455.70% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.41M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.41M.
Fairly Valued
The company’s latest PE is -0.25, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 228.38K shares, increasing 38.27% quarter-over-quarter.